Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:OCX

OncoCyte (OCX) Stock Price, News & Analysis

OncoCyte logo

About OncoCyte Stock (NASDAQ:OCX)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$2.60
$3.44
52-Week Range
N/A
Volume
100,514 shs
Average Volume
58,260 shs
Market Capitalization
$90.80 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.06
Consensus Rating
Moderate Buy

Company Overview

OncoCyte Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
27th Percentile Overall Score

OCX MarketRank™: 

OncoCyte scored higher than 27% of companies evaluated by MarketBeat, and ranked 799th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    OncoCyte has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    OncoCyte has only been the subject of 3 research reports in the past 90 days.

  • Read more about OncoCyte's stock forecast and price target.
  • Earnings Growth

    Earnings for OncoCyte are expected to grow in the coming year, from ($2.57) to ($1.40) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of OncoCyte is -0.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of OncoCyte is -0.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Read more about OncoCyte's valuation and earnings.
  • Short Interest

    There is no current short interest data available for OCX.
  • Dividend Yield

    OncoCyte does not currently pay a dividend.

  • Dividend Growth

    OncoCyte does not have a long track record of dividend growth.

  • Short Interest

    There is no current short interest data available for OCX.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for OncoCyte this week, compared to 1 article on an average week.
  • Search Interest

    Only 1 people have searched for OCX on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, OncoCyte insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 2.05% of the stock of OncoCyte is held by insiders.

  • Percentage Held by Institutions

    55.35% of the stock of OncoCyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about OncoCyte's insider trading history.
Receive OCX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for OncoCyte and its competitors with MarketBeat's FREE daily newsletter.

OCX Stock News Headlines

OncoCyte (NASDAQ:OCX) Shares Up 16.3% - Still a Buy?
Tap into the $65B ‘Shroom Boom’
Functional mushrooms are booming—and one company is turning that trend into a high-growth, recurring revenue model. With a patent-pending device that grows mushrooms at home in just 8 days, they’re giving early investors a unique shot at stock bonuses and fast liquidity.
See More Headlines

OCX Stock Analysis - Frequently Asked Questions

OncoCyte Corporation (NASDAQ:OCX) announced its earnings results on Monday, May, 12th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.24) by $0.02. The business had revenue of $2.14 million for the quarter, compared to the consensus estimate of $0.13 million. OncoCyte had a negative net margin of 1,516.06% and a negative trailing twelve-month return on equity of 215.59%.
Read the conference call transcript
.

OncoCyte's stock reverse split on the morning of Tuesday, July 25th 2023.The 1-20 reverse split was announced on Tuesday, July 25th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, July 25th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that OncoCyte investors own include Alibaba Group (BABA), Meta Platforms (META), Fulcrum Therapeutics (FULC), VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), CymaBay Therapeutics (CBAY) and Ford Motor (F).

Company Calendar

Last Earnings
5/12/2025
Today
7/25/2025
Next Earnings (Estimated)
8/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Medical Services
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:OCX
CIK
1642380
Employees
120
Year Founded
N/A

Price Target and Rating

High Price Target
$8.00
Low Price Target
$4.00
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
($3.53)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$60.66 million
Net Margins
-1,516.06%
Pretax Margin
-1,514.57%
Return on Equity
-215.59%
Return on Assets
-27.23%

Debt

Debt-to-Equity Ratio
0.20
Current Ratio
3.74
Quick Ratio
3.70

Sales & Book Value

Annual Sales
$3.84 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($0.70) per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
28,599,000
Free Float
28,013,000
Market Cap
$90.80 million
Optionable
No Data
Beta
0.97
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

This page (NASDAQ:OCX) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners